US00461U1051
US00461U1051
Aclaris Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 563.77M EUR | 739.67M EUR | 523.7M EUR | 362.7M EUR |
Enterprise Value | 468.18M EUR | 720.5M EUR | 495.04M EUR | 342.74M EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | -4.86x | -- | -- | -- |
Price to Sales | 68.59x | 90x | 62.59x | 56.93x |
Price to Book | 4.3x | 5.94x | 3.65x | 3.52x |
EV/Revenue | 56.96x | 87.66x | 59.17x | 53.8x |
EV/EBITDA | -5.47x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -7.44% | -8.41% | -9.82% | -9.18% |